Current Trends in IVIG Therapy
February 2012 - Vol. 9 No. 2 - Page #32

Q&A with Jerry Siegel, 


Pharmacy Purchasing & Products: Given the 30-year history of IVIG, how has therapeutic use of this product evolved over time?
Jerry Siegel: Initially, intravenous immunoglobulin (IVIG) was used to replace the use of intramuscular immunoglobulin G (IgG) for the treatment of patients with primary immune deficiency (PID). Due to the limited volume and physical pain associated with the injections, doses of IgG were low and relatively ineffective in preventing infection in patients with PID. The first IVIG products to be introduced enabled much higher doses of IgG to be administered at a single time with a single infusion. The original doses of IgG were smaller (125-250 mg/kg) compared to today where average IVIG doses are in the range of 400-500 mg/kg for replacement therapy.

To read the full article, please log in or register.


Current Issue

Our mission is to provide health system professionals with information to streamline operations and promote patient safety.

As a requester to PP&P you will receive all monthly issues, as well as our annual Resource Guide of product and service providers and all of our timely supplements on hot-button issues.

Thank you for reading PP&P, and we look forward to providing you with information to enhance the field.